Literature DB >> 24428400

Differentiation of acute fatty liver of pregnancy from syndrome of hemolysis, elevated liver enzymes and low platelet counts.

Hisanori Minakami1, Mamoru Morikawa, Takahiro Yamada, Takashi Yamada, Rina Akaishi, Ryutaro Nishida.   

Abstract

As proposed criteria (Swansea criteria) for the diagnosis of acute fatty liver of pregnancy (AFLP) do not include antithrombin (AT) activity, diagnosis of AFLP may be delayed. The aim of this review is to underscore problems in the differential diagnosis of AFLP and the syndrome of hemolysis, elevated liver enzymes and low platelet counts (HELLP syndrome) and to facilitate prompt diagnosis of AFLP. Published works dealing with liver dysfunction in pregnancy, HELLP syndrome and AFLP were reviewed. AFLP and HELLP syndrome shared common clinical, laboratory, histological and genetic features, and differential diagnosis between them was often difficult. However, HELLP syndrome was likely to occur in patients with hypertension, but AFLP occurred often in the absence of hypertension. In addition, AFLP was exclusively associated with pregnancy-induced antithrombin deficiency (PIATD). Approximately 50% of patients with AFLP did not have thrombocytopenia at presentation. As the Swansea criteria for AFLP did not include PIATD, diagnosis of AFLP was delayed until manifestation of life-threatening complications; 60% of women were admitted to intensive care and 15% to a specialist liver unit. In conclusion, incorporation of AT activity of less than 65% into the diagnostic criteria for AFLP may facilitate suspicion and prompt diagnosis of AFLP, decrease uncertainty regarding the diagnosis of AFLP, and contribute to better investigation and understanding of the process leading to the development of liver dysfunction.
© 2014 The Authors. Journal of Obstetrics and Gynaecology Research © 2014 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  antithrombin activity; blood vessel permeability; liver dysfunction; pre-eclampsia; thrombocytopenia

Mesh:

Substances:

Year:  2014        PMID: 24428400     DOI: 10.1111/jog.12282

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  7 in total

1.  Acute fatty liver of pregnancy associated with severe acute pancreatitis: A case report.

Authors:  Cássio Vieira de Oliveira; Alecsandro Moreira; Julio P Baima; Leticia de C Franzoni; Talles B Lima; Fabio da S Yamashiro; Kunie Yabuki Rabelo Coelho; Ligia Y Sassaki; Carlos Antonio Caramori; Fernando G Romeiro; Giovanni F Silva
Journal:  World J Hepatol       Date:  2014-07-27

2.  Acute Fatty Liver of Pregnancy-Differential Diagnosis.

Authors:  Adam Morton
Journal:  Am J Gastroenterol       Date:  2017-08       Impact factor: 10.864

3.  Outcomes and risk factors of patients with acute fatty liver of pregnancy: a multicentre retrospective study.

Authors:  Qiang Gao; Xin Qu; Xiukai Chen; Jicheng Zhang; Fen Liu; Suochen Tian; Chunting Wang
Journal:  Singapore Med J       Date:  2018-01-03       Impact factor: 1.858

Review 4.  Acute Fatty Liver Disease of Pregnancy: Updates in Pathogenesis, Diagnosis, and Management.

Authors:  Joy Liu; Tara T Ghaziani; Jacqueline L Wolf
Journal:  Am J Gastroenterol       Date:  2017-03-14       Impact factor: 10.864

Review 5.  Acute Fatty Liver of Pregnancy: Pathophysiology, Anesthetic Implications, and Obstetrical Management.

Authors:  Emily E Naoum; Lisa R Leffert; Hovig V Chitilian; Kathryn J Gray; Brian T Bateman
Journal:  Anesthesiology       Date:  2019-03       Impact factor: 7.892

6.  HELLP Syndrome or Acute Fatty Liver of Pregnancy: A Differential Diagnostic Challenge: Common Features and Differences.

Authors:  Werner Rath; Panagiotis Tsikouras; Patrick Stelzl
Journal:  Geburtshilfe Frauenheilkd       Date:  2020-05-18       Impact factor: 2.915

7.  A case of chronic hepatitis B merged with acute fatty liver of pregnancy with severe coagulopathy.

Authors:  Risa Fukushima; Kotoe Kamata; Fumiko Ariyoshi; Masashi Yanaki; Minoru Nomura; Makoto Ozaki
Journal:  JA Clin Rep       Date:  2019-01-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.